Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age

Maertens, Kirsten; Caboré, Raïssa Nadège; Huygen, Kris; Vermeiren, Sandra; Hens, Niel; Damme, Pierre Van; Leuridan, Elke

doi:10.1016/j.vaccine.2016.04.066

Cited by 83 publications

(57 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specifically, maternally derived IgG antibodies can inhibit immune responses against the same or related antigens after primary vaccination series in early infancy, a phenomenon termed "immunological blunting". This blunting usually dissipates after the booster dose [15,24]. Blunting has been observed for maternal antibodies acquired after natural infection or maternal immunization, notably with measles and polio vaccines, although the effect varies considerably between vaccines and studies [15,25].…”

Section: The Effect Of Maternal Immunization In Infantsmentioning

confidence: 99%

Maternal immunization: where are we now and how to move forward?

et al. 2018

View full text Add to dashboard Cite

Pregnancy and the postpartum period are associated with elevated risks to both mother and infant from infectious disease. Vaccination of pregnant women, also called maternal immunization, has the potential to protect pregnant women, foetuses and infants from several vaccinepreventable diseases. Maternal immunoglobulin G antibodies are actively transferred through the placenta to provide passive immunity to new-borns during the first months of life, until the time for infant vaccinations or until the period of greatest susceptibility has passed. Currently, inactivated influenza, tetanus, and pertussis vaccines are recommended during pregnancy in many countries, but other vaccines may also be administered to pregnant women when risk factors are present. Several new vaccines with a specific indication for use during pregnancy are under development (e.g. respiratory syncytial virus and group B streptococcus vaccines). Years of experience suggest that maternal immunization against influenza, tetanus or pertussis has an acceptable safety profile, is well tolerated, effective and confers significant benefits to pregnant women and their infants. This review describes the principles of maternal immunization and provides an update of the recent evidence regarding the use and timing of maternal immunization. Finally, the barriers preventing wider vaccination coverage and the current limitations in addressing these are also described (Supplementary Material). KEY MESSAGESMaternal immunization gives pregnant women greater protection against infectious diseases; induces high levels of maternal antibodies that can be transferred to the foetus; and helps protect new-borns during their first months of life, until they are old enough to be vaccinated. Pregnant women and new-borns are more vulnerable to infectious diseases than the overall population; nevertheless, vaccination rates are often low in pregnant women. This review provides an update of the recent evidence regarding the use and timing of maternal immunization and describes the barriers preventing wider vaccination uptake and the current limitations in addressing these. ARTICLE HISTORY

show abstract

Section: The Effect Of Maternal Immunization In Infantsmentioning

confidence: 99%

Maternal immunization: where are we now and how to move forward?

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated that immunization during pregnancy with acellular pertussis vaccine (Tdap) produces an elevation in IgG class antibody titres in pregnant women, and consequently an elevation in antibody titres in newborn plasma as well 1,[19][20][21] . This phenomenon is not observed when maternal immunization is performed prior to pregnancy 22 .…”

Section: Immunological Basis Of Antenatal Tdap Vaccinementioning

confidence: 99%

Vacunación con pertussis en el embarazo: una estrategia segura y efectiva para proteger al lactante menor

Villena

Vidal²,

Carrillo

et al. 2017

Rev. chil. pediatr.

View full text Add to dashboard Cite

Vacunación con pertussis en el embarazo: una estrategia segura y efectiva para proteger al lactante menor Keywords:Whooping cough, Bordetella pertussis, diphtheria-tetanuspertussis vaccine AbstractWhooping cough is an immune preventable disease that can be life threatening. Despite infant immunization starting at 2 month of age, there are many cases and outbreaks in our country and also around the world, with a high risk of mortality especially in infants under 6 month of age. It has been proposed that antenatal vaccination with acellular pertussis component (Tdap) would be useful, safe and effective since it transfers a high antibody rate to the child, reducing the incidence of pertussis in this group by 85%. No higher incidence of adverse effects has been found in pregnant women with this vaccine. This strategy has been implemented in several developed and Latin American countries. The purpose of this manuscript is to review and discuss the benefits of antenatal vaccination with Tdap. It was concluded that maternal immunization with Tdap vaccine should be promoted to prevent infection and associated mortality in infants under 6 months of age by Bordetella pertussis.

show abstract

“…Por razones de seguridad, se ha analizado la posible interferencia de esta medida con la respuesta inmune de las vacunas pediátricas habituales del primer semestre de vida del niño y los datos señalan una reducción discreta a moderada de los niveles de anticuerpos para difteria y toxina pertussis en hijos de madres vacunadas 21,22 . Aun así se alcanzan concentraciones de anticuerpos protectoras para H. influenzae b, tétanos, difteria y hepatitis B y la interferencia desaparece después de las dosis de refuerzo en el segundo año de vida 21,23 . La seguridad de esta estrategia queda además respaldada por los datos epidemiológicos provenientes de aquellos países que ya han adoptado esta estrategia en los últimos tres a cuatro años, donde no se ha visto un resurgimiento de otras enfermedades infecciosas prevenibles por vacunas.…”

Section: Estrategias Propuestasunclassified

Estrategias para proteger al recién nacido y lactante menor de 6 meses de la coqueluche: Posición del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología (CCI)

Potı́n¹,

Fíca²,

Véliz³

et al. 2016

Rev. chil. infectol.

View full text Add to dashboard Cite

, en representación del CCI Strategies to protect the newborn and infants under 6 months of age against pertussis. Statement of the Advisory Committee for Immunizations of the Chilean Infectious Diseases SocietyIn recent years there have been Pertussis outbreaks not seen in the last 50 years affecting adults, adolescents and children and causing deaths in young unvaccinated infants. In Chile an outbreak of Pertussis started in year 2011, leaving 16 infants less than 3 months dead during this year, twice the number seen in a non epidemic year. These children were infected before receiving the programmatic vaccines indicated at 2, 4 and 6 months of age, usually from close contacts, especially their mothers. Pertussis control has not been possible for several reasons, such as limited immunity duration of available vaccines and their poor impact on nasopharyngeal carriage, situation that keeps the agent's circulation and transmission, condition often asymptomatic or unrecognized. Additionally, the use of acellular vaccines appears to be a determining factor because they induce an immune response with poor immune memory and consequently a short time duration. The acellular vaccines with reduced antigen content, available for adolescents and adults, has allowed the evaluation of various strategies but none has succeeded in reducing infant mortality. Recently a new strategy of vaccinating pregnant women against Pertussis in the second or third semester has shown remarkable results reducing up to 90% infant deaths due to Pertussis infection. This strategy prevents mother´s infection avoiding child infection through respiratory droplets and also provides the child with antibodies from placental transmission. Improved pertussis vaccines are required, in the meantime the Committee considers that the pregnant immunization strategy, between the 27 and 36 weeks, with acellular pertussis vaccine should be included in our national vaccine program.Key words: Pertussis infection, whooping cough, maternal immunization. Palabras clave: Coqueluche, tos ferina, vacunación materna. Situación epidemiológicaL a coqueluche o tos convulsiva, constituye junto al sarampión, una de las dos enfermedades inmunoprevenibles de mayor transmisibilidad, siendo cada una de ellas capaz de enfermar cerca de 12 a 17 personas susceptibles. A pesar del uso de vacunas eficaces por más de 60 años, la coqueluche continúa siendo un problema de salud pública provocando anualmente unas 200.000 muertes de lactantes en el mundo 1 . En forma cíclica, cada dos a cinco años ocurren brotes epidémicos, incluso en países con altas coberturas de vacunación y entre los años 2010 y 2012 se alcanzaron las incidencias más altas de los últimos 20 a 50 años en países desarrollados como E.U.A. . Estos aumentos de la incidencia afectan a lactantes bajo 6 meses de edad, que por su edad no han iniciado la vacunación o no la han completado o tampoco poseen ya inmunidad pasiva transferida desde la madre. Los brotes también afectan a escolares o adolescentes y adultos, en los que ...

show abstract

Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age

Cited by 83 publications

References 27 publications

Maternal immunization: where are we now and how to move forward?

Maternal immunization: where are we now and how to move forward?

Vacunación con pertussis en el embarazo: una estrategia segura y efectiva para proteger al lactante menor

Estrategias para proteger al recién nacido y lactante menor de 6 meses de la coqueluche: Posición del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología (CCI)

Contact Info

Product

Resources

About